Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631917 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 774
- Enrollment target
NCT00631917 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 774 participants.
The verdict
NCT00631917, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 774 participants
- Enrollment target
Study Summary
This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
Interventions
- DRUG Ramipril
- DRUG Aliskiren
- OTHER Placebo to Ramipril
- OTHER Placebo to Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 774 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00631917
The ClinicalTrials.gov registry entry for NCT00631917 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 774 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ramipril is the first listed.
NCT00631917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00631917 about?
NCT00631917 is a clinical study titled "A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension". This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
What is the current status of trial NCT00631917?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 774 participants. The study started on 2008-02. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00631917?
The interventions under investigation include: Ramipril (DRUG), Aliskiren (DRUG), Placebo to Ramipril (OTHER), Placebo to Aliskiren (OTHER).
Who is sponsoring clinical trial NCT00631917?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.